Universal (UVV) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
23 Nov, 2025Executive summary
Operating income rose to $33.8 million, nearly doubling year-over-year, driven by a 147% increase in Tobacco Operations segment income, despite a slight revenue decline to $593.8 million in Q1 FY2026.
Ingredients Operations revenue grew 5% to $89.1 million, but segment income fell 42% due to less favorable product mix, tariff impacts, and higher fixed costs.
Uncommitted tobacco inventory remained low at 11%, reflecting strong customer demand and more typical buying patterns.
Net income attributable to shareholders was $8.5 million ($0.34 per diluted share), up from $0.1 million ($0.01 per share) last year; adjusted net income was $9.6 million ($0.38 per share).
Financial highlights
Gross profit margin improved to 19.2% from 16.1% year-over-year.
Operating income was $33.8 million, up from $17.2 million year-over-year; adjusted operating income was $34.9 million.
Cash and cash equivalents stood at $178.4 million, up $76.7 million sequentially; $355 million available under revolving credit facility.
Net debt was $1.07 billion, down $47.1 million year-over-year; net debt to net capitalization ratio improved to 42% from 44%.
SG&A expenses increased by $0.5 million to $79.2 million, mainly due to higher compensation and legal fees.
Outlook and guidance
Flue-cured and burley tobacco crop sizes (excluding China) are expected to increase by 25% and 45%, respectively, in FY2026, with potential for oversupply and margin pressure by year-end.
Focus remains on maximizing tobacco business and driving organic growth in Ingredients Operations, leveraging expanded facilities and new product capabilities.
Capital expenditures expected to be $45–$55 million over the next twelve months for maintenance and growth projects.
Optimism for margin improvement in ingredients as volumes increase, though execution on pipeline projects is required.
Available capital resources are expected to exceed working capital and capital expenditure needs over the next year.
Latest events from Universal
- Revenue and profit fell, but tobacco stayed strong and liquidity improved with new credit facility.UVV
Q3 20269 Feb 2026 - Q1 FY2025 revenue up 15% and operating income up 56%, with strong demand across segments.UVV
Q1 20252 Feb 2026 - Strategy centers on tobacco leadership, scaling ingredients, and sustainable, profitable growth.UVV
28th Annual ICR Conference 202613 Jan 2026 - Shareholders will vote on directors, executive pay, and auditor ratification amid strong results and ESG progress.UVV
Proxy Filing1 Dec 2025 - Proxy covers director elections, say-on-pay, auditor ratification, and strong ESG focus.UVV
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor, with updated proxy card.UVV
Proxy Filing1 Dec 2025 - Revenue up 7% to $2.95B, operating income up 5%, with strong segment growth and improved liquidity.UVV
Q4 202526 Nov 2025 - Revenue and net income increased, offsetting margin pressures and supporting growth initiatives.UVV
Q2 202613 Nov 2025 - Digital-first growth, strong Asia expansion, and premium wellness products drive performance.UVV
Investor Presentation27 Jun 2025